Logo-jnp
J Nephropathol. 2016;5(2): 79-83. doi: 10.15171/jnp.2016.14
PMID: 27152294        PMCID: PMC4844913

Case Report

Acute oxalate nephropathy associated with orlistat

Youshay Humayun 1 * , Kenneth C. Ball 1, Jack R. Lewin 2, Anna A. Lerant 3,4, Tibor Fülöp 1

Cited by CrossRef: 11


1- Lumlertgul N, Siribamrungwong M, Jaber B, Susantitaphong P. Secondary Oxalate Nephropathy: A Systematic Review. Kidney International Reports. 2018;3(6):1363 [Crossref]
2- Bargagli M, Tio M, Waikar S, Ferraro P. Dietary Oxalate Intake and Kidney Outcomes. Nutrients. 2020;12(9):2673 [Crossref]
3- Hti Lar Seng N, Lohana P, Chandra S, Jim B. The Fatty Kidney and Beyond: A Silent Epidemic. The American Journal of Medicine. 2023;136(10):965 [Crossref]
4- Zhu J, Hu M, Liang Y, Zhong M, Chen Z, Wang Z, Yang Y, Luo Z, Zeng W, Li J, Du Y, Liu Y, Yang C. Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database. Heliyon. 2024;10(14):e34837 [Crossref]
5- Žižka O, Haluzík M, Jude E. Pharmacological Treatment of Obesity in Older Adults. Drugs Aging. 2024;41(11):881 [Crossref]
6- Gotthardt J, Bello N. Can we win the war on obesity with pharmacotherapy?. Expert Review of Clinical Pharmacology. 2016;9(10):1289 [Crossref]
7- Zhang X, Pawar A, Greene E. 72-Year-Old Woman With Fatigue, Confusion, and Severe Acute Renal Failure. Mayo Clinic Proceedings. 2018;93(10):1520 [Crossref]
8- Ni Z, Tian X, Zhao W, Hu W, Lv J, Sun X, Zhang Y, Zhang Y, Zhang Y, Li B, Liu F. The detrimental effects and mechanisms of Orlistat in disrupting energy homeostasis and reproduction in Daphnia magna. Aquatic Toxicology. 2025;279:107201 [Crossref]
9- Afshan S, Farah Musa A, Echols V, Lerant A, Fülöp T. Persisting Hypocalcemia After Surgical Parathyroidectomy: The Differential Effectiveness of Calcium Citrate Versus Calcium Carbonate With Acid Suppression. The American Journal of the Medical Sciences. 2017;353(1):82 [Crossref]
10- Noonin C, Thongboonkerd V. Beneficial roles of gastrointestinal and urinary microbiomes in kidney stone prevention via their oxalate-degrading ability and beyond. Microbiological Research. 2024;282:127663 [Crossref]
11- Solomon L, Nixon A, Ogden L, Nair B. Orlistat-induced oxalate nephropathy: an under-recognised cause of chronic kidney disease. BMJ Case Reports. 2017;:bcr-2016-218623 [Crossref]
12- Pilitsi E, Farr O, Polyzos S, Perakakis N, Nolen-Doerr E, Papathanasiou A, Mantzoros C. Pharmacotherapy of obesity: Available medications and drugs under investigation. Metabolism. 2019;92:170 [Crossref]